AMI Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

AMI Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35M	Buy	+66,949	New	+$34.3M	2.01%	25

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

AMI Asset Management's VRTX Position: Q3 2026 in Review

AMI Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 66,949 shares worth $35M. The stake represents 2.01% of the portfolio and ranks #25 among its holdings.

346 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

AMI Asset Management held 66,949 shares of Vertex Pharmaceuticals worth $35M as of Q3 2026.
Vertex Pharmaceuticals was a new AMI Asset Management position in Q3 2026.
Vertex Pharmaceuticals made up 2.01% of AMI Asset Management's portfolio in Q3 2026, its #25 holding.
346 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on AMI Asset Management's 13F filing for Q3 2026, filed 20 Oct 2026.